Gilead Sciences Inc. (GILD) said Tuesday it is buying Phenex Pharmaceuticals AG's Farnesoid X Receptor (FXR) program, which comprises small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). As part of the deal, Gilead will pay the privately-held German company an upfront payment plus additional payments based on certain milestones that could be worth up to $470 million.
By Dana Mattioli, Ryan Dezember and Chelsey Dulaney
Coach Inc. has agreed to buy upscale shoe brand Stuart Weitzman in a deal valued at up to $574 million, a rare acquisition for the purse retailer as it seeks to expand its reach.
Green Dot Corporation (NYSE:GDOT) today announced it has appointed Chief
Technology Officer and Executive Vice President of Product Development,
Kuan Archer, to Chief Operating Officer (COO), effective January 1.
International, Inc. (NYSE: CIR), a leading provider of valves and
other highly engineered products for markets including oil & gas, power
generation and aerospace & defense, today announced the divestiture of
two of its non-strategic businesses.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.